AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

Clinical trial NCT07218809 · RECRUITING

Trial details

NCT number: NCT07218809
Sponsor: AstraZeneca
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Epithelial Ovarian Cancer

Start date: 2025-12-29
Primary completion: 2028-11-17
Enrollment: 1100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.